vs
Axsome Therapeutics, Inc.（AXSM）与BOSTON BEER CO INC（SAM）财务数据对比。点击上方公司名可切换其他公司
BOSTON BEER CO INC的季度营收约是Axsome Therapeutics, Inc.的2.4倍（$461.6M vs $191.2M），Axsome Therapeutics, Inc.同比增速更快（57.4% vs -4.1%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs -10.7%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
波士顿啤酒公司是美国知名酿酒企业，1984年由吉姆·科赫与朗达·卡尔曼联合创立。旗下首款产品以美国开国元勋、独立运动先驱塞缪尔·亚当斯命名，后续陆续推出多个自有品牌，2019年正式完成与角鲨头酿酒厂的合并，是北美精酿啤酒行业的核心参与者之一。
AXSM vs SAM — 直观对比
营收规模更大
SAM
是对方的2.4倍
$191.2M
营收增速更快
AXSM
高出61.5%
-4.1%
两年增速更快
AXSM
近两年复合增速
-10.7%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $191.2M | $461.6M |
| 净利润 | — | — |
| 毛利率 | — | 46.4% |
| 营业利润率 | -33.1% | 12.4% |
| 净利率 | — | — |
| 营收同比 | 57.4% | -4.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $2.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMSAM
| Q1 26 | $191.2M | $461.6M | ||
| Q4 25 | $196.0M | $385.7M | ||
| Q3 25 | $171.0M | $537.5M | ||
| Q2 25 | $150.0M | $587.9M | ||
| Q1 25 | $121.5M | $453.9M | ||
| Q4 24 | $118.8M | $402.3M | ||
| Q3 24 | $104.8M | $605.5M | ||
| Q2 24 | $87.2M | $579.1M |
净利润AXSMSAM
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-22.5M | ||
| Q3 25 | $-47.2M | $46.2M | ||
| Q2 25 | $-48.0M | $60.4M | ||
| Q1 25 | $-59.4M | $24.4M | ||
| Q4 24 | $-74.9M | $-38.8M | ||
| Q3 24 | $-64.6M | $33.5M | ||
| Q2 24 | $-79.3M | $52.3M |
毛利率AXSMSAM
| Q1 26 | — | 46.4% | ||
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 50.8% | ||
| Q2 25 | — | 49.8% | ||
| Q1 25 | — | 48.3% | ||
| Q4 24 | — | 39.9% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 46.0% |
营业利润率AXSMSAM
| Q1 26 | -33.1% | 12.4% | ||
| Q4 25 | -13.8% | -8.6% | ||
| Q3 25 | -27.0% | 11.5% | ||
| Q2 25 | -24.5% | 14.0% | ||
| Q1 25 | -46.9% | 7.4% | ||
| Q4 24 | -61.1% | -13.9% | ||
| Q3 24 | -59.8% | 7.6% | ||
| Q2 24 | -89.5% | 12.2% |
净利率AXSMSAM
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -5.8% | ||
| Q3 25 | -27.6% | 8.6% | ||
| Q2 25 | -32.0% | 10.3% | ||
| Q1 25 | -48.9% | 5.4% | ||
| Q4 24 | -63.1% | -9.6% | ||
| Q3 24 | -61.7% | 5.5% | ||
| Q2 24 | -91.0% | 9.0% |
每股收益（稀释后）AXSMSAM
| Q1 26 | — | $2.16 | ||
| Q4 25 | $-0.55 | $-1.97 | ||
| Q3 25 | $-0.94 | $4.25 | ||
| Q2 25 | $-0.97 | $5.45 | ||
| Q1 25 | $-1.22 | $2.16 | ||
| Q4 24 | $-1.54 | $-3.23 | ||
| Q3 24 | $-1.34 | $2.86 | ||
| Q2 24 | $-1.67 | $4.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $305.1M | $164.1M |
| 总债务越低越好 | $70.0M | — |
| 股东权益账面价值 | — | $682.6M |
| 总资产 | $713.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMSAM
| Q1 26 | $305.1M | $164.1M | ||
| Q4 25 | $322.9M | $223.4M | ||
| Q3 25 | $325.3M | $250.5M | ||
| Q2 25 | $303.0M | $212.4M | ||
| Q1 25 | $300.9M | $152.5M | ||
| Q4 24 | $315.4M | $211.8M | ||
| Q3 24 | $327.3M | $255.6M | ||
| Q2 24 | $315.7M | $219.3M |
总债务AXSMSAM
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益AXSMSAM
| Q1 26 | — | $682.6M | ||
| Q4 25 | $88.3M | $846.3M | ||
| Q3 25 | $73.7M | $911.0M | ||
| Q2 25 | $73.1M | $912.3M | ||
| Q1 25 | $53.2M | $897.0M | ||
| Q4 24 | $57.0M | $916.2M | ||
| Q3 24 | $92.9M | $1.0B | ||
| Q2 24 | $102.9M | $1.0B |
总资产AXSMSAM
| Q1 26 | $713.6M | $1.2B | ||
| Q4 25 | $689.8M | $1.2B | ||
| Q3 25 | $669.3M | $1.2B | ||
| Q2 25 | $639.8M | $1.3B | ||
| Q1 25 | $596.7M | $1.2B | ||
| Q4 24 | $568.5M | $1.3B | ||
| Q3 24 | $561.5M | $1.4B | ||
| Q2 24 | $548.2M | $1.4B |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
SAM
暂无分部数据
